Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVX754 vs Lamivudine in Treatment-Experienced HIV-1 Patients with M184V Mutation
NCT00126880Phase 2Completed
- Sponsor
- Avexa Limited
- Start
- Jul 2005
- Primary completion
- Jan 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of apricitabine in human immunodeficiency virus type 1 infection (HIV-1) (3 arms), sponsored by Avexa Limited. Primary endpoints: Change from baseline in HIV RNA levels at day 21 and Time-weighted average change from baseline in HIV RNA levels through 21 days. Started Jul 2005; status: completed.
02
Drugs
apricitabine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00126880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00126880.